Thank you to everyone who sent me feedback on this podcast. This episode is based on a suggestion from Drew. In this episode, I discuss bioequivalence studies and generic drug development. I will refer to guidance documents from both the European Medicines Agency or EMA and the US Food and Drug Administration or FDA. First, I will start with a discussion of the definition of bioequivalence or BE. Then I will discuss the statistical basis for bioequivalence and how you can leverage that for study design. And I will end with some unique challenges related to bioequivalence. Throughout, I will give practical suggestions based on my experiences in the past with BE studies.
Links discussed in the show:
• EMA guidance on bioequivalence
• FDA guidance on statistical approaches to bioequivalence (December 2022)
• FDA statistical approaches to BE (January 2001)
• FDA guidance on BE studies (2022)
• FDA product-specific guidances on BE
• Lecture from Helmut Schütz on finding intra-subject variability (or CV%) for power calculations
• You can connect with me on LinkedIn and send me a message
Copyright Teuscher Solutions LLC
All Rights Reserved
Popular Podcasts
Dateline NBC
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations.
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
The Nikki Glaser Podcast
Every week comedian and infamous roaster Nikki Glaser provides a fun, fast-paced, and brutally honest look into current pop-culture and her own personal life.